Efficacy News and Research

RSS

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Boehringer Ingelheim today announced the completion of patient enrolment for a Phase IIa clinical trial investigating a new interferon-free, all-oral, direct-acting antiviral combination treatment for patients with genotype-1a chronic hepatitis C virus infection.

10 Sep 2013

Relmada Therapeutics reports positive results from pivotal pharmacokinetic study of LevoCap ER

Relmada Therapeutics Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced a positive outcome of its pivotal pharmacokinetic study for LevoCap ER. Based on the positive outcome of this study, Relmada is now preparing the Phase III development program and is planning to submit a request with the FDA to discuss the final pathway to the New Drug Application for this product during the fourth quarter of this year.

10 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Patients with COPD show improvements in lung function with olodaterol

Data from the olodaterol Phase 3 clinical program, presented for the first time at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, showed the addition of olodaterol 5 and 10 µg delivered once daily via the Respimat® inhaler provided improvements in lung function in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

10 Sep 2013

Banook Central Imaging, Oncodesign partner to expand use of new approaches in pharmaco-imaging

Oncodesign, a contract research laboratory dedicated to the discovery of new anticancer therapies, and Banook Central Imaging, a company specializing in the centralized reading of medical images, today announce the start of a partnership to expand the use of new approaches in pharmaco-imaging.

10 Sep 2013

Experts develop website to help navigate new challenges posed by breast density notification laws

A team of California-based breast imagers and breast cancer risk specialists have developed a website to help navigate the new challenges posed by breast density notification laws, according to a special report published online in the journal Radiology.

10 Sep 2013

Oncodesign, Banook Central Imaging To Develop Cancer Biomarkers

...

9 Sep 2013

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found.

9 Sep 2013

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

Novartis announced new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 - indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in lung function, shortness of breath and health-related quality of life for chronic obstructive pulmonary disease (COPD) patients versus all comparators1,2. These data were part of 39 respiratory abstracts presented at the European Respiratory Society (ERS) Annual Congress in Barcelona, Spain.

9 Sep 2013

D&A PHARMA to present 3 clinical studies for ALCOVER in 14th Congress of ESBRA at Warsaw

D&A PHARMA, a leading company in the Addiction therapeutic area, announces today its strong participation in the 14th Congress of European Company of Biomedical Search on the Alcoholism (ESBRA), which will be held in Warsaw from September 8th to 11th.

7 Sep 2013

FUJIFILM SonoSite gets CE mark approval for X-Porte Ultrasound Kiosk

FUJIFILM SonoSite, Inc., specialists in designing cutting-edge ultrasound tools and world-leading education for access to point-of-care visualization, today announced CE mark approval for its newest generation of point-of-care ultrasound: the X-Porte Ultrasound Kiosk.

7 Sep 2013

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

Clinical trial of Grafix for treatment of chronic diabetic foot ulcers accepted for presentation at SAWC

Osiris Therapeutics, Inc. (NASDAQ: OSIR), announced today that its multi-center, randomized, controlled clinical trial evaluating the safety and effectiveness of Grafix® for the treatment of chronic diabetic foot ulcers has been accepted for podium presentation at the upcoming Symposium on Advanced Wound Care (SAWC) in Las Vegas on Friday, September 27, 2013.

7 Sep 2013

Tactile Medical launches ambulatory device to heal venous leg ulcers

Tactile Medical (formerly Tactile Systems Technology Inc.), a Minneapolis-based developer and provider of home therapy devices, launched a first-of-its-kind ambulatory device for patients with chronic wounds. The ACTitouch Adaptive Compression Therapy system combines two proven therapies - intermittent and sustained compression - in one device to heal venous leg ulcers.

7 Sep 2013

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Viamet Pharmaceuticals, Inc. announced today the initiation of the phase 2 clinical program for its antifungal agent VT-1161. The initial phase 2 study is designed to evaluate the safety and efficacy of VT-1161 in the treatment of vulvovaginal candidiasis (VVC) and is being conducted at leading clinical centers in the United States.

7 Sep 2013

Prophylactic cranial irradiation beneficial in elderly SCLC patients

Prophylactic cranial irradiation improves survival in elderly patients with limited-stage small-cell lung cancer, analysis of US epidemiologic data indicates.

6 Sep 2013

Cellular Biomedicine Group reports interim results of Phase I/IIa clinical trial for Knee Osteoarthritis

Cellular Biomedicine Group, Inc. today announced the interim results of its Phase I/IIa clinical trial for human adipose-derived mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis, which tests the safety and efficacy of intra-articular injections of autologous (patient's own) haMPCs in order to reduce inflammation and repair damaged joint cartilage.

6 Sep 2013

Efficacy News and Research

Boehringer Ingelheim completes patient enrolment for interferon-free hepatitis C treatment

Relmada Therapeutics reports positive results from pivotal pharmacokinetic study of LevoCap ER

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Patients with COPD show improvements in lung function with olodaterol

Banook Central Imaging, Oncodesign partner to expand use of new approaches in pharmaco-imaging

Experts develop website to help navigate new challenges posed by breast density notification laws

Oncodesign, Banook Central Imaging To Develop Cancer Biomarkers

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Once-daily COPD portfolio data from Novartis presented at European Respiratory Society (ERS) Annual Congress

D&A PHARMA to present 3 clinical studies for ALCOVER in 14th Congress of ESBRA at Warsaw

FUJIFILM SonoSite gets CE mark approval for X-Porte Ultrasound Kiosk

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

Clinical trial of Grafix for treatment of chronic diabetic foot ulcers accepted for presentation at SAWC

Tactile Medical launches ambulatory device to heal venous leg ulcers

Viamet initiates phase 2 clinical trial of antifungal agent VT-1161 for treatment of vulvovaginal candidiasis

Prophylactic cranial irradiation beneficial in elderly SCLC patients

Cellular Biomedicine Group reports interim results of Phase I/IIa clinical trial for Knee Osteoarthritis

Scientists develop robotic systems for image-guided removal of hard-to-reach brain tumors

Chemotherapy best second-line option for EGFR wild-type NSCLC

Rigel Cuts 30 Jobs, Refocuses On Three Clinical Programs

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News